NCT01497522 - Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes | Biotech Hunter

Enrollment

183

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Vildagliptin

vildagliptin 50 mg twice daily

DRUG

Placebo

Matching Placebo of vildagliptin 50 mg twice daily

Trial Locations (20)

810-0001

Novartis Investigative Site, Fukuoka

819-0168

Novartis Investigative Site, Fukuoka

800-0296

Novartis Investigative Site, Kitakyushu

830-8543

Novartis Investigative Site, Kurume

831-0016

Novartis Investigative Site, Ohkawa-city

210-0014

Novartis Investigative Site, Kawasaki

221-0802

Novartis Investigative Site, Yokohama

607-8062

Novartis Investigative Site, Kyoto

615-0035

Novartis Investigative Site, Kyoto

569-1096

Novartis Investigative Site, Takatsuki

362-8588

Novartis Investigative Site, Ageo

113-0031

Novartis Investigative Site, Bunkyo-ku

134-0084

Novartis Investigative Site, Edogawa-ku

192-0046

Novartis Investigative Site, Hachiōji

204-0021

Novartis Investigative Site, Kiyose

105-7390

Novartis Investigative Site, Minato-ku

108-0075

Novartis Investigative Site, Minato-ku

177-0051

Novartis Investigative Site, Nerima-ku

141-0032

Novartis Investigative Site, Shinagawa-ku

171-0021

Novartis Investigative Site, Toshima-ku